Fast Track and Breakthrough Therapy are two distinct FDA designation programs that speed up drug development, but they differ significantly in scope and intensity of FDA involvement. Fast Track is a broader program designed to facilitate the development of drugs that treat serious conditions and fill an unmet medical need. Breakthrough Therapy goes further, offering more intensive FDA guidance for drugs that show early clinical evidence of substantial improvement over existing therapies. The sections below unpack the key differences, eligibility criteria, and strategic considerations for each designation.
How do Fast Track and Breakthrough Therapy designations actually work?
Fast Track designation is a development program that gives sponsors more frequent communication with the FDA and the opportunity for rolling review, meaning the FDA evaluates completed sections of a New Drug Application (NDA) or Biologics License Application (BLA) before the full submission is complete. Breakthrough Therapy designation offers all of the Fast Track benefits, plus intensive guidance from senior FDA staff throughout the development process, including organizational commitment from the FDA to work closely with the sponsor.
Both designations are granted by the FDA based on a formal request, which can be submitted at the time of an Investigational New Drug (IND) application or any time afterward. The FDA aims to respond to Fast Track requests within 60 days and Breakthrough Therapy requests within 60 days as well, though in practice the agency often responds faster for Breakthrough Therapy given its higher priority status.
The core mechanism behind both programs is the same: they exist to accelerate the development and review of treatments for serious or life-threatening conditions. The difference lies in how much direct FDA involvement the sponsor receives and what level of clinical evidence is required to qualify.
What are the eligibility criteria for each designation?
To qualify for Fast Track designation, a drug must treat a serious or life-threatening condition and demonstrate the potential to address an unmet medical need. The bar for preliminary clinical evidence is relatively low at this stage, and preclinical data can sometimes be sufficient to support the request.
Breakthrough Therapy has a higher eligibility threshold. In addition to treating a serious condition, the drug must show preliminary clinical evidence indicating it may offer a substantial improvement over available therapies on at least one clinically significant endpoint. This means the sponsor needs at least some early human data, typically from Phase 1 or Phase 2 trials, before applying.
The distinction matters for timing. A company can request Fast Track designation early in development, even before human trials begin, while Breakthrough Therapy typically requires clinical data in hand. This makes Fast Track more accessible during early-stage drug development strategy planning.
What benefits does Breakthrough Therapy offer that Fast Track does not?
Breakthrough Therapy designation provides all the benefits of Fast Track, plus three additional advantages that Fast Track alone does not offer: intensive guidance from senior FDA staff during drug development, organizational commitment from the FDA to involve experienced reviewers and managers, and cross-disciplinary meetings with FDA leadership to discuss the drug’s development program.
In practical terms, this means a Breakthrough Therapy sponsor can expect:
- More frequent and substantive meetings with FDA reviewers throughout development
- Guidance on the most efficient clinical trial designs to support approval
- Feedback from senior FDA officials who have authority to resolve development questions quickly
- A collaborative relationship with the FDA that can significantly reduce late-stage surprises
These additional benefits can substantially reduce development timelines and lower the risk of costly late-stage failures. For companies with limited resources, the intensive FDA collaboration that comes with Breakthrough Therapy can be more valuable than the designation label itself.
When should a company apply for Fast Track versus Breakthrough Therapy?
Apply for Fast Track when you are in early development, have a drug targeting a serious condition with an unmet need, and want to establish a more collaborative relationship with the FDA before clinical data is available. Apply for Breakthrough Therapy when you have preliminary clinical evidence showing your drug may substantially outperform existing options.
From a drug development strategy perspective, the decision often comes down to timing and available data. If you are preclinical or very early in Phase 1, Fast Track is the appropriate first step. As clinical data matures and shows strong signals of superiority, upgrading to or directly applying for Breakthrough Therapy becomes the logical next move.
Companies should also consider their resources. Breakthrough Therapy requires more active engagement with the FDA, which demands internal bandwidth and regulatory expertise to manage effectively. The intensive collaboration is a benefit, but it also requires preparation and responsiveness from the sponsor’s team. Working with an experienced regulatory consulting partner can make a significant difference in how efficiently these interactions are managed.
Can a drug hold both Fast Track and Breakthrough Therapy designations simultaneously?
Yes, a drug can hold both Fast Track and Breakthrough Therapy designations at the same time, and this is relatively common. Because Breakthrough Therapy automatically confers all Fast Track benefits, holding both designations simultaneously does not add additional benefits beyond what Breakthrough Therapy already provides. However, some sponsors initially receive Fast Track and later receive Breakthrough Therapy as their clinical data strengthens.
In practice, once a drug receives Breakthrough Therapy designation, the Fast Track designation becomes largely redundant since all Fast Track features are already included. The FDA does not require a sponsor to relinquish Fast Track status upon receiving Breakthrough Therapy, so both can coexist on the same program without conflict.
How do these designations interact with Accelerated Approval and Priority Review?
Fast Track and Breakthrough Therapy designations are development programs, while Accelerated Approval and Priority Review are approval mechanisms. They operate at different stages of the regulatory process and can be combined. A drug with Fast Track or Breakthrough Therapy designation may also qualify for Accelerated Approval, Priority Review, or both, depending on the nature of the disease and the strength of the evidence.
Here is how each mechanism works and where it fits:
- Accelerated Approval allows a drug to be approved based on a surrogate endpoint reasonably likely to predict clinical benefit, with a requirement for confirmatory trials post-approval
- Priority Review shortens the FDA’s review timeline from the standard 10 months to 6 months for drugs that offer major advances in treatment
- Fast Track and Breakthrough Therapy facilitate development and can make a drug eligible for Priority Review at the time of submission
A well-designed drug development strategy often layers these mechanisms together. For example, a Breakthrough Therapy drug treating a rare cancer might also pursue Accelerated Approval based on tumor response rate and receive Priority Review at submission, creating a fast and efficient path from clinical development to market approval.
How Starodub Supports Your Regulatory Designation Strategy
Navigating FDA designation programs requires both scientific rigor and strategic clarity, and that is exactly where we come in. At Starodub, we help biopharmaceutical companies and startup founders identify the right designations for their products, prepare compelling designation requests, and manage the ongoing FDA interactions that follow. Our team brings hands-on experience across small molecules, biologics, and complex products, so we understand the nuances that make or break a designation request.
Specifically, we support clients with:
- Assessing eligibility for Fast Track, Breakthrough Therapy, Accelerated Approval, and Priority Review
- Drafting and submitting designation requests to the FDA with the right framing and supporting data
- Preparing for FDA meetings and managing the agency interactions that follow designation
- Integrating designation strategy into a broader regulatory and clinical development plan
- Advising on EU equivalents such as PRIME designation for companies targeting both markets
Whether you are preparing your first IND or refining a late-stage development program, we offer the regulatory expertise to help you move efficiently toward approval. Contact Starodub today to discuss your product’s designation strategy and find the fastest, most credible path to market.
Related Articles
- Can regulatory intelligence help predict FDA draft guidances early?
- What are the most common gaps in regulatory submission dossiers?
- How do you measure the effectiveness of a GMP compliance program?
- How do you navigate medical device regulations for combination products?
- Can you improve approval timelines by working with regulatory experts?
This content was generated with the help of AI and it may contain mistakes
